

JUN 04 2002

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



SEARCHED

for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

2

Complete If Known

Application Number	10/087,227
Filing Date	February 27, 2002
First Named Inventor	Alan F. Schatzberg et al.
Group Art Unit	1646
Examiner Name	Unassigned

Attorney Docket Number

STAN-261

U.S. PATENT DOCUMENTS

Examiner Initials'	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials'	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
ATM			WO 01/37840A1		Schatzberg et al.	05/31/01		
			WO 99/59596		Schatzberg et al.	11/25/99		
			WO 99/17779		Schatzberg et al.	04/15/99		
HJM			WO 95/17192		Cohn et al.	06/29/1995		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
HJM		HEDLEY-WHITE et al., "Effect of Dexamethasone on Blood-Brain Barrier in the Normal Mouse" <i>Ann. Neurol.</i> (1986) 19:373-377	
		NEUWELT et al., "The Effect of Steroids on gentamicin delivery to brain after blood-brain barrier disruption" <i>J. Neurosurg.</i> (1990) 72:123-126	
		PAUL et al., "Inhibition of Blood-Barrier Disruption in Experimental Allergic Encephalomyelitis by Short-term Therapy with Dexamethasone or Cyclosporin A" <i>Int. J. Immunopharm.</i> (1995) 17:497-503	
		ZIYLAN et al., "Effect of Dexamethasone on Transport of α-Aminoisobutyric Acid and Sucrose Across the Blood-Brain Barrier" <i>J. Neurochem.</i> (1988) 51:1338-1342	
		ZIYLAN et al., "Regional Alterations in Blood-to-Brain Transfer of α-Aminoisobutyric Acid and Sucrose, after Chronic Administration and Withdrawal of Dexamethasone" <i>J. Neurochem.</i> (1989) 52:684-689	
		ZIYLAN et al., "Changes in the Permeability of the Blood-Brain Barrier in Acute Hyperammonemia" <i>Mol. And Chem Neuropath.</i> (1993) 20:203-218	
HJM		Bornheim et al. "Effect of Cytochrome P450 Inducers on Cocaine-Mediated Hepatotoxicity" <i>Toxicology Tox. And Appl. Pharm.</i> (1988) 150:158-165	

O I P &
JUN 04 1997
PATENT & TRADEMARK OFFICE

911X	LONG et al. "Blood-Brain Barrier: Endogenous Modulation by Adrenal-Cortical Function" <i>Science</i> (1985) 227:1580-1583	
911X	IWEN et al "Enhancement of Ketoconazole Penetration across the Blood-brain Barrier of Mice by Dimethyl Sulfoxide" <i>Antimicrobial Agents and Chemotherapy</i> , Oct. 1986, p. 614-618	
911X	PERFECT et al. "Comparison of Itraconazole and Fluconazole in Treatment of Cryptococcal Meningitis and Candida Pyelonephritis in Rabbits" <i>Antimicrobial Agents and Chemotherapy</i> , APR. 1986, p. 579-583	
911X	GAILLARD et al. "Corticosteroid Regulation of Blood-Brain Barrier Permeability" <i>Society for Neuroscience</i> , Vol. 23, 1997 pp 229 Abstract XP-001057484	

Examiner Signature	James H. Meamer	Date Considered	7/7/03
--------------------	-----------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.